RayKnowChina Research Map
Shortlist0

RecruitingB-cell acute lymphoblastic leukaemiaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 9 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 3 years to 18 years; sex: all

    Registered eligibility fields

  2. Patients who received specified chemotherapy before CNCT19 infusion

    Exclusion criterion 9

  3. Karnofsky (age ≥ 16 years) performance status ≥ 70 or Lansky (age < 16 years) performance status ≥ 50 at screening

    Inclusion criterion 6

  4. Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive).

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05667506, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Inclusion Criteria:

  • Signed written informed consent prior to any study procedures (patient and/or parent or legal guardian)
  • Age 3 to 18. Weight ≥10kg
  • Relapsed or refractory acute lymphoblastic leukemia (ALL).
  • Documentation of CD19 tumor expression demonstrated in bone marrow or peripheral blood within 3 months before screening.
  • Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening.
  • Karnofsky (age ≥ 16 years) performance status ≥ 70 or Lansky (age < 16 years) performance status ≥ 50 at screening
  • Organ function requirements: All patients must have adequate renal and liver functions

Key Exclusion Criteria:

  • Active Central Nervous System (CNS) involvement by malignancy.
  • Isolated extra-medullary disease relapse.
  • Patients with Burkitt's lymphoma/leukemia, mixed phenotypic acute leukemia and Chronic Myelogenous Leukemia in Blast Crisis
  • History of concomitant genetic syndrome
  • Patients with acute graft-versus-host disease (GVHD) or moderate-to-severe chronic GVHD within 4 weeks before screening.
  • Active systemic autoimmune disease
  • Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive).
  • Patients with active infections at screening.
  • Patients who received specified chemotherapy before CNCT19 infusion
  • Radiotherapy before CNCT19 infusion:

Non-CNS site of radiation completed < 4 weeks prior to CNCT19 Infusion; CNS directed radiation completed < 8 weeks prior to CNCT19 infusion.

  • Donor lymphocyte infusion (DLI) must be stopped > 6 week prior to CNCT19 infusion.
  • Has had treatment with any prior CAR-T therapy.
  • Life expectancy < 3 months.

Quoted from ClinicalTrials.gov, NCT05667506, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05667506, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05667506